Literature DB >> 31872359

The link between interleukin-1β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.

Hirotaka Mori1, Masumi Sukegawa2, Masahiko Fukatsu1, Takahiro Sano1, Hiroshi Takahashi1, Kayo Harada1, Satoshi Kimura1, Hiroshi Ohkawara1, Kenichi Nakamura3, Masayuki Mita3, Tomiyoshi Saito3, Yoichi Hamazaki4, Masatsugu Ohta2, Takayuki Ikezoe5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31872359     DOI： 10.1007/s00277-019-03896-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

1.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

2.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Authors:  Andreas Hochhaus; Richard A Larson; François Guilhot; Jerald P Radich; Susan Branford; Timothy P Hughes; Michele Baccarani; Michael W Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D Menssen; Hagop Kantarjian; Stephen G O'Brien; Brian J Druker
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

3.  Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice.

Authors:  Benjamin W Van Tassell; Amit Varma; Fadi N Salloum; Anindita Das; Ignacio M Seropian; Stefano Toldo; Lisa Smithson; Nicholas N Hoke; Vinh Q Chau; Roshanak Robati; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2010-02       Impact factor: 3.105

4.  Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Authors:  Torsten Dahlén; Gustaf Edgren; Mats Lambe; Martin Höglund; Magnus Björkholm; Fredrik Sandin; Anders Själander; Johan Richter; Ulla Olsson-Strömberg; Lotta Ohm; Magnus Bäck; Leif Stenke
Journal:  Ann Intern Med       Date:  2016-06-14       Impact factor: 25.391

5.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.

Authors:  G Liuzzo; L M Biasucci; J R Gallimore; R L Grillo; A G Rebuzzi; M B Pepys; A Maseri
Journal:  N Engl J Med       Date:  1994-08-18       Impact factor: 91.245

6.  The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p.

Authors:  Masumi Sukegawa; Xiangmin Wang; Chie Nishioka; Bin Pan; Kailin Xu; Hiroshi Ohkawara; Yoichi Hamasaki; Masayuki Mita; Kenichi Nakamura; Masatoshi Okamoto; Hiromi Shimura; Masatsugu Ohta; Takayuki Ikezoe
Journal:  Leuk Res       Date:  2017-05-05       Impact factor: 3.156

7.  Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.

Authors:  Massimo Breccia; Matteo Molica; Irene Zacheo; Alessandra Serrao; Giuliana Alimena
Journal:  Ann Hematol       Date:  2014-10-12       Impact factor: 3.673
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.